{
    "Trade/Device Name(s)": [
        "VIDAS\u00ae RUB IgG Assay"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K080766",
    "Predicate Device Reference 510(k) Number(s)": [
        "K954045"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFX"
    ],
    "Summary Letter Date": "December 19, 2008",
    "Summary Letter Received Date": "December 22, 2008",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.3510"
    ],
    "Regulation Name(s)": [
        "Rubella virus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "serology"
    ],
    "Analyte(s)": [
        "Rubella IgG"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VIDAS automated instruments"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme Linked Fluorescent Assay (ELFA)",
        "Two-step enzyme immunoassay sandwich method"
    ],
    "Methodologies": [
        "Immunoassay",
        "Enzyme-linked fluorescent assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for VIDAS\u00ae RUB IgG Assay for measurement of IgG antibodies to rubella virus in human serum using ELFA technology.",
    "Indications for Use Summary": "Intended for quantitative and qualitative measurement of IgG antibodies to rubella virus in human serum to aid in the determination of immune status to rubella; not established for screening of cord blood, neonatal samples, or immunocompromised individuals.",
    "fda_folder": "Microbiology"
}